OSIR Insider Trading Activity and SEC Form 4 Filings
OSIR insider trading summary
No open-market insider purchases or sales of Osiris Therapeutics, Inc. (OSIR) have been reported on SEC Form 4 in the past 12 months.
Latest OSIR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 10, 2015 | Alla Danilkovitch | Chief Scientific Officer | Sell | $44K (2,425 @ $18.22) |
| Jun 4, 2015 | Gregory Ivan Law | Principal Accounting Officer | Buy | $2K (100 @ $18.83) |
| May 27, 2015 | Philip R Jacoby Jr | Chief Financial Officer | Sell | $371K (20,000 @ $18.55) |
| May 29, 2014 | Matthew Paul Neumayer | Principal Accounting Officer | Sell | $8K (500 @ $15.55) |
| May 27, 2014 | Matthew Paul Neumayer | Principal Accounting Officer | Sell | $60K (3,750 @ $16.10) |
| May 21, 2014 | Philip R Jacoby Jr | Chief Financial Officer | Sell | $246K (15,947 @ $15.43) |
| Mar 14, 2014 | Michelle LeRoux Williams | Chief Scientific Officer | Sell | $166K (11,934 @ $13.91) |
| Mar 13, 2014 | Michelle LeRoux Williams | Chief Scientific Officer | Sell | $707K (50,000 @ $14.14) |
| Nov 25, 2013 | Philip R Jacoby Jr | Chief Financial Officer | Sell | $294K (18,372 @ $15.99) |
| Nov 15, 2013 | Michelle LeRoux Williams | Chief Scientific Officer | Sell | $380K (24,500 @ $15.50) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.